3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Ventricular Dysfunction
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Hypertension
1
Essential Hypertension
1
Cardiotoxicity
1
Breast Neoplasms
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Prednisone
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
atezolizumab
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Enalapril
×
Clear all
NCT01968200
2023-06-28
ICOS-ONE
European Institute of Oncology
Phase 3
Unknown
268 enrolled